Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial

Veronique Verhoeven, Maja Lopez Hartmann, Roy Remmen, Johan Wens, Sandra Apers, Paul Van Royen, Veronique Verhoeven, Maja Lopez Hartmann, Roy Remmen, Johan Wens, Sandra Apers, Paul Van Royen

Abstract

Background: In recent years, red yeast rice (RYR) supplements have been marketed aggressively as a natural way to lower cholesterol; however, the large majority of commercially available products have not been studied according to current research standards.

Methods: In a double blind placebo controlled randomized trial, 52 physicians and their spouses with a total cholesterol level of > 200 mg/dL were randomly allocated to receive a RYR extract or placebo for 8 weeks. As a primary outcome measure, we compared the before-after difference in lipid levels between both groups. As secondary outcome measures we looked at side-effects, CK elevation and a change in cardiovascular risk.

Results: LDL (low density lipoprotein) cholesterol was lowered with 36 mg/dL (22%) and total cholesterol with 37 mg/dL (15%) in the intervention group. This result was statistically significant as compared to the control group, in which no reduction in total cholesterol and LDL was observed (p < 0.001). There was no marked difference in CK (creatine kinase)-elevation or reported side-effects between study groups. In 5/31 participants in the intervention group, the lipid lowering effect resulted in lower cardiovascular risk as measured with SCORE (Systematic COronary Risk Evaluation).

Conclusions: The RYR formulation under study was effective in lowering cholesterol and LDL cholesterol in this study population. RYR therapy may be an attractive and relatively well studied alternative in patients who are intolerant for statins or who have objections against pharmacological lipid lowering. However, consumers need to be warned that the actual content of commercially available preparations is not assured by governmental regulations, which raises effectiveness and safety issues.

Trial registration: Clinicaltrials.gov, nr: NCT01558050.

Figures

Figure 1
Figure 1
Consort 2010 flow diagram.
Figure 2
Figure 2
Absolute before and after levels of serum lipids in study participants.

References

    1. Ying Sing S, T’ien Jung K'ai W. Sun E-T and Sun S-C, transl. London: Pennsylvania State University Press; 1966. Chinese technology in the seventeenth century; pp. 291–294.
    1. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170:1722–1727. doi: 10.1001/archinternmed.2010.382.
    1. Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz ID Jr. Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clin Chem. 1992;38:150–160.
    1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1407–1408. doi: 10.1136/bmj.326.7404.1407.
    1. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
    1. Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, Collins R. Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378:2013–2020.
    1. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) European guidelines on cardiovascular disease prevention in clinical practice (version 2012) Eur Heart J. 2012;33:1635–1701.
    1. Harper CR, Jacobson TA. Evidence-based management of statin myopathy. Curr Atheroscler Rep. 2010;12:322–30. doi: 10.1007/s11883-010-0120-9.
    1. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol. 2011;27:635–662. doi: 10.1016/j.cjca.2011.05.007.
    1. Sirtori CR, Mombelli G, Triolo M, Laaksonen R. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Ann Med. 2012;44:419–432. doi: 10.3109/07853890.2011.582135.
    1. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99:1409–1412. doi: 10.1016/j.amjcard.2006.12.063.
    1. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol. 2012;110:526–529. doi: 10.1016/j.amjcard.2012.04.026.
    1. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy - a systematic review. J Am Coll Cardiol. 2007;49:2231–2237. doi: 10.1016/j.jacc.2007.02.049.
    1. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM, Li S. Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689–1693. doi: 10.1016/j.amjcard.2008.02.056.
    1. Li JJ, Lu ZL, Kou WR, Chen Z, Wu YF, Yu XH, Zhao YC. Chinese Coronary Secondary Prevention Study Group. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS) J Clin Pharmacol. 2009;49:947–956. doi: 10.1177/0091270009337509.
    1. Reinhart KM, Woods JA. Strategies to preserve the use of statins in patients with previous muscular adverse effects. Am J Health Syst Pharm. 2012;69:291–300. doi: 10.2146/ajhp100700.
    1. Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab. 2010;95:2015–2022. doi: 10.1210/jc.2009-2689.
    1. Venero CV, Venero JV, Wortham DC, Thompson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol. 2010;105:664–666. doi: 10.1016/j.amjcard.2009.10.045.
    1. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830–839. doi: 10.7326/0003-4819-150-12-200906160-00006. W147-9.
    1. Lapi F, Gallo E, Bernasconi S, Vietri M, Menniti-Ippolito F, Raschetti R, Gori L, Firenzuoli F, Mugelli A, Vannacci A. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J ClinPharmacol. 2008;66:572–574.
    1. Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med. 2006;145:474–475. doi: 10.7326/0003-4819-145-6-200609190-00021.
    1. Gordon RY, Becker DJ. The role of red yeast rice for the physician. Curr Atheroscler Rep. 2011;13:73–80. doi: 10.1007/s11883-010-0145-0.
    1. Sirtori CR, Galli C, Anderson JW, Sirtori E, Arnoldi A. Functional foods for dyslipidaemia and cardiovascular risk prevention. Nutr Res Rev. 2009;22:244–261.
    1. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1:CD004816.
    1. Prasad V, Vandross A. Cardiovascular primary prevention: how high should we set the bar? Arch Intern Med. 2012;172:656–659. doi: 10.1001/archinternmed.2012.812.
    1. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, McAlister FA, Wiebe N, Manns B. Alberta Kidney Disease Network. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ. 2011;183:E1189–E1202.
    1. Stagnitti M. Trends in statins utilization and expenditures for the U.S. civilian noninstitutionalized population, 2000 and 2005. (MEPS Statistical Brief. No. 205). . Accessed September 11, 2012.
    1. Roberfroid D, Dubois C, Vrijens F, Camberlin C, Farfan-Portet M. Statines in Belgie: evolutie in het gebruik en invloed van het terugbetalingsbeleid. KCE report, 2010, English version. accessed 11/9/2012.
    1. , accessed 26/9/2012.
    1. Krumholz HM, Hayward RA. Shifting views on lipid lowering therapy. BMJ. 2010;341:c3531. doi: 10.1136/bmj.c3531.
    1. Lebenthal Y, Horvath A, Dziechciarz P, Szajewska H, Shamir R. Are treatment targets for hypercholesterolemia evidence based? Systematic review and meta-analysis of randomised controlled trials. Arch Dis Child. 2010;95:673–680. doi: 10.1136/adc.2008.157024.
    1. Martin SS, Blumenthal RS, Miller M. LDL cholesterol: the lower the better. Med Clin North Am. 2012;96:13–26. doi: 10.1016/j.mcna.2012.01.009.
    1. Campbell A. Natural ways to lower your cholesterol. Diabetes Self Manag. 2010;27:40–46.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다